GLPwatch
Amycretin
Pipeline · Amylin and GLP-1 receptor co-agonist
Last updated 2026-05-28Amycretin is an experimental drug that works by activating both amylin and GLP-1 receptors in the body, which are involved in regulating blood sugar and appetite. It is being developed as a potential treatment for type 2 diabetes and obesity, though it has not yet been approved for any use.
AI summary of the sources below.
| Mechanism | Amylin and GLP-1 receptor co-agonist Mimics amylin and GLP-1, two hormones that curb appetite and slow digestion to help control blood sugar. |
|---|---|
| Status | Pipeline |
| Branded products | — (none approved) |
| Manufacturer(s) | novo-nordisk |
How Amycretin connects
- Maker Novo Nordisk
- Trials 1 trials
- Research 5 papers
Trials (1)
Top research (5)
- Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study.
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial.
- The effect of amycretin, a unimolecular glucagon-like peptide-1 and amylin receptor agonist, on body weight and metabolic dysfunction in mice and rats.
- GLP-1 and amylin receptor multiagonism with amycretin for obesity management.
- Amycretin in obesity: Mechanisms, clinical efficacy, and future perspectives.